Zytiga data presents new threat to Provenge

As if Dendreon ($DNDN) didn't have enough to worry about, Johnson & Johnson's ($JNJ) prostate cancer pill Zytiga has now shown itself effective in patients who haven't yet received chemotherapy. That means it could gain broader use, in a population of patients that's larger than its current target.

On the advice of an independent committee, J&J's Janssen unit unblinded a clinical trial of Zytiga plus prednisone in 1,088 men who hadn't yet been treated with chemotherapy. Now, placebo patients in the study can get access to Zytiga, and J&J can prep for an FDA filing for a new indication. If approved, the new use would give Zytiga more ammunition in its competition with Dendreon's Provenge vaccine.

Indeed, Dendreon stock dropped on the news, as analysts called the J&J data a new threat to the vaccine. Robin Karnausakas of Deustche Bank said the study "could lead to some weakness in Provenge sales," in a note to investors today (as quoted by Bloomberg). Already Provenge has seen its prospects dented by Zytiga uptake, as reimbursement questions and a complicated treatment procedure put some doctors off the Dendreon product.

- find the release from Janssen
- read the Bloomberg coverage
- get more from the Wall Street Journal
- see the coverage at Minyanville

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.